In the current study, we evaluated peripheral blood TCR-ß chain repertoires in advanced NSCLC before and after treatment with durvalumab (anti-PD-L1) to identify how TCR repertoires are associated with outcome. Here, CD274 is linked to non-small cell lung carcinoma.